ArticleCancer medicine2026
The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving Immunotherapy.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPreexisting chronic obstructive pulmonary disease (COPD) is associated with favorable clinical efficacy in NSCLC patients undergoing immune checkpoint inhibitors (ICIs). But the impact of COPD comorbidities on SCLC patients that are receiving immunotherapy remains unclear.
methodsPatients with extensive-stage SCLC (ES-SCLC) received carboplatin combined with etoposide (carboplatin-etoposide, EC group) or durvalumab plus carboplatin-etoposide (EC + PD-L1 group) treatment as first line therapy were collected. In EC + PD-L1 group, survival of patients with preexisting COPD and patients without preexisting COPD were further compared.
resultsA total of 120 ES-SCLC patients who met the eligibility criteria were included in this study. The median overall survival (OS) and the progression-free survival (PFS) were significantly longer in the EC + PD-L1 group than in the EC group, with a HR of 0.37 (95% CI, 0.16-0.88; p = 0.001) and 0.42 (95% CI, 0.23-0.77; p < 0.001), respectively. We further stratified groups by COPD status in EC + PD-L1 group and EC group. In EC + PD-L1 group, PFS was significantly prolonged in COPD group compared with the non-COPD group, with a HR of 0.57 (95% CI, 0.35-0.96; p = 0.018). The COPD group demonstrated a numerically higher objective response rate than the non-COPD group, though the difference was not statistically significant (p = 0.292). No OS benefit was found between the groups.
conclusionPreexisting COPD status may be associated with favorable clinical efficacy in ES-SCLC patients undergoing ICIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.